REG - JP Morgan Sec LLC Xeris Pharmaceutical - Xeris Pharmaceuticals, Inc 8.3

Xeris Biopharma HoldingsAnnouncement

11/08/2021 15:25

RNS Number : 3501I
  
J.P. Morgan Securities LLC
  
11 August 2021
  
 

Ap19
 
 
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 




Name of person dealing (Note 1)


J.P. Morgan Securities LLC




Company dealt in


Xeris Pharmaceuticals, Inc.




Class of relevant security to which the dealings being disclosed relate (Note 2)


$0.001 common stock




Date of dealing


10 August 2021




 
2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)




 


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


3,293,365                4.95


134,113             0.20




(2) Derivatives (other than options)


124,443                0.19


 




(3) Options and agreements to purchase/sell


 


 




Total


3,417,808             5.14


134,113             0.20



 
 
 
 
 
 
 




 

 
 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 




 
Purchase/sale


 
Number of relevant securities


 
Price per unit (USD)
 
(Note 5)




Purchases
Purchases
 
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales


1 
 1 
 
 100 
 4,200 
 6,296 
 300 
 1,201 
 672 
 8,000 
 1,700 
 8,900 
 26,848 
 5,100 
 600 
 34,671 
 9,843 
 13,358 
 13,783 
 1,000 
 400 
 29,572 
 8,107 
 1,200 
 700 
 11,700 
 4,362 
 21,985 
 8,650 
 11,600 
 4,600 
 5,939 
 1,700 
 2,400 
 416 
 3,060 
 295 
 3,100 
 700 
 1,900 
 100 
 100 
 800 
 300 
 200 
 500


2.3100          USD
2.3150          USD
                        
2.3000          USD
2.3035          USD
2.3050          USD
2.3067          USD
2.3100          USD
2.3115          USD
2.3146          USD
2.3147          USD
2.3150          USD
2.3161          USD
2.3180          USD
2.3183          USD
2.3187          USD
2.3188          USD
2.3198          USD
2.3200          USD
2.3210          USD
2.3225          USD
2.3241          USD
2.3242          USD
2.3250          USD
2.3257          USD
2.3262          USD
2.3264          USD
2.3272          USD
2.3277          USD
2.3296          USD
2.3300          USD
2.3339          USD
2.3350          USD
2.3367          USD
2.3384          USD
2.3392          USD
2.3398          USD
2.3400          USD
2.3450          USD
2.3500          USD
2.3550          USD
2.3700          USD
2.3800          USD
2.3833          USD
2.4050          USD
2.4150          USD




 
 
 
(b)      Derivatives transactions (other than options transactions)
 




Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(USD) (Note 5)




 


 


 


 




 
 
 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 
 




Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)




 


 


 


 


 


 


 




 
 
(ii)      Exercising
 




Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)




 


 


 




 
 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 




Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)




 


 


 




 
                          
 
Ap21
 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 
voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 
or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 
     None
 
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 




Date of disclosure


 11 August 2021




Contact name


Alwyn Basch




Telephone number


0207 742 7407




If a connected EFM, name of offeree/offeror with which connected


N/A




If a connected EFM, state nature of connection (Note 10)


N/A




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ISEZZGMRDMZGMZM